2005
Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental Disorders
Jou R, Handen B, Hardan A. Retrospective Assessment of Atomoxetine in Children and Adolescents with Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychopharmacology 2005, 15: 325-330. PMID: 15910217, DOI: 10.1089/cap.2005.15.325.Peer-Reviewed Original ResearchConceptsConners' Parent Rating ScalePervasive developmental disorderConcomitant medicationsClinical Global Impression ScaleTolerability of atomoxetinePlacebo-controlled studyGlobal Impression ScaleGlobal improvement itemSevere mood swingsDevelopmental disordersCPRS subscaleMost patientsClinic registryRetrospective studyImpression ScaleTreatment responseTreatment doseClinical informationPatientsAtomoxetineSecondary symptomsParent Rating ScaleMood swingsRating ScaleRetrospective assessment
2004
Psychostimulant treatment of adults with mental retardation and attention‐deficit hyperactivity disorder
Jou R, Handen B, Hardan A. Psychostimulant treatment of adults with mental retardation and attention‐deficit hyperactivity disorder. Australasian Psychiatry 2004, 12: 376-379. DOI: 10.1111/j.1440-1665.2004.02130.x.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderHyperactivity disorderTreatment of ADHDTolerability of psychostimulantsAberrant Behavior Checklist-Community VersionChart reviewMental retardationDouble-blind placebo-controlled studyProspective open-label studyPsychostimulant treatmentClinical Global Impression ScaleDevelopmental disabilitiesOpen-label studyPlacebo-controlled studyConsecutive adult outpatientsIrritability subscaleRetrospective chart reviewGlobal Impression ScaleGlobal improvement itemTreatment terminationAdverse eventsAdult outpatientsImpression ScaleAdultsPsychostimulantsPsychostimulant Treatment of Adults With Mental Retardation and Attention-Deficit Hyperactivity Disorder
Jou R, Handen B, Hardan A. Psychostimulant Treatment of Adults With Mental Retardation and Attention-Deficit Hyperactivity Disorder. Australasian Psychiatry 2004, 12: 376-379. PMID: 15715811, DOI: 10.1080/j.1440-1665.2004.02130.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmphetamineAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsClinical Trials as TopicDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationHumansIntellectual DisabilityIrritable MoodMethylphenidateMotor ActivityPersonality AssessmentQuality of LifeSocial BehaviorTreatment OutcomeConceptsAttention deficit hyperactivity disorderAberrant Behavior Checklist-Community VersionHyperactivity disorderTreatment of ADHDTolerability of psychostimulantsChart reviewMental retardationDouble-blind placebo-controlled studyProspective open-label studyPsychostimulant treatmentClinical Global Impression ScaleDevelopmental disabilitiesOpen-label studyPlacebo-controlled studyConsecutive adult outpatientsIrritability subscaleRetrospective chart reviewGlobal Impression ScaleGlobal improvement itemTreatment terminationAdverse eventsAdult outpatientsImpression ScaleAdultsPsychostimulantsA Retrospective Assessment of Topiramate in Children and Adolescents with Pervasive Developmental Disorders
Hardan A, Jou R, Handen B. A Retrospective Assessment of Topiramate in Children and Adolescents with Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychopharmacology 2004, 14: 426-432. PMID: 15650499, DOI: 10.1089/cap.2004.14.426.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderOpen-label retrospective studyClinical Global Impression ScalePlacebo-controlled studyRetrospective chart reviewNovel antiepileptic drugGlobal Impression ScaleGlobal improvement itemDevelopmental disordersOpenlabel studyConcomitant medicationsChart reviewSkin rashAdjunctive treatmentSeizure disorderAntiepileptic drugsOutpatient clinicRetrospective studyMean doseImpression ScaleMedical recordsTreatment responsePatientsSide effectsTreatment duration